SG11202003200VA - Adenovirus and uses thereof - Google Patents

Adenovirus and uses thereof

Info

Publication number
SG11202003200VA
SG11202003200VA SG11202003200VA SG11202003200VA SG11202003200VA SG 11202003200V A SG11202003200V A SG 11202003200VA SG 11202003200V A SG11202003200V A SG 11202003200VA SG 11202003200V A SG11202003200V A SG 11202003200VA SG 11202003200V A SG11202003200V A SG 11202003200VA
Authority
SG
Singapore
Prior art keywords
adenovirus
Prior art date
Application number
SG11202003200VA
Inventor
Taco Uil
Soumitra Roy
Selina Khan
Jerôme Custers
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11202003200VA publication Critical patent/SG11202003200VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SG11202003200VA 2017-10-31 2018-10-30 Adenovirus and uses thereof SG11202003200VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199347 2017-10-31
PCT/EP2018/079704 WO2019086450A1 (en) 2017-10-31 2018-10-30 Adenovirus and uses thereof

Publications (1)

Publication Number Publication Date
SG11202003200VA true SG11202003200VA (en) 2020-05-28

Family

ID=60413036

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003200VA SG11202003200VA (en) 2017-10-31 2018-10-30 Adenovirus and uses thereof

Country Status (13)

Country Link
US (1) US11872281B2 (en)
EP (1) EP3703722A1 (en)
JP (1) JP7438943B2 (en)
KR (1) KR20200083510A (en)
CN (1) CN111356466A (en)
AU (1) AU2018359492B2 (en)
BR (1) BR112020007698A2 (en)
CA (1) CA3079210A1 (en)
EA (1) EA202091104A1 (en)
IL (1) IL274220A (en)
MX (1) MX2020004492A (en)
SG (1) SG11202003200VA (en)
WO (1) WO2019086450A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576326B2 (en) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ Oncolytic adenovirus composition
ES2933174T3 (en) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP2019536468A (en) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ Synthetic adenovirus targeting tumors and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (en) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド Complementary adenoviral vector systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
ES2333425T5 (en) 1995-06-15 2012-08-28 Crucell Holland B.V. Packaging systems for human recombinant adenovirus intended for gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000509614A (en) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド Adenovirus E1-complementation cell line
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc Adenovirus carrying gag gene hiv vaccine
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
EP1320621A4 (en) 2000-09-15 2005-11-23 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
NZ530245A (en) 2001-06-22 2007-04-27 Wistar Inst Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
SI1497438T1 (en) 2002-04-25 2010-03-31 Crucell Holland Bv Means and methods for the production of adenovirus vectors
PL376792A1 (en) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
EP2163260B1 (en) 2004-01-23 2017-03-15 MSD Italia S.r.l. Chimpanzee adenovirus vaccine carriers
BRPI0516048A (en) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batch of a replicating defective recombinant adenovirus based on a subgroup c serotype
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
BRPI0819783A2 (en) 2007-11-28 2015-06-23 Univ Pennsylvania Simian subfamily and adenovirus sadv-39, -25.2, -26, -30, -37 and -38 and uses thereof.
MX2011004292A (en) 2008-11-03 2011-05-31 Crucell Holland Bv Method for the production of adenoviral vectors.
AU2010209938A1 (en) * 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
JP5250155B2 (en) 2010-02-15 2013-07-31 クルセル ホランド ベー ヴェー Method for producing Ad26 adenovirus vector
US9526777B2 (en) 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
WO2013016591A1 (en) 2011-07-26 2013-01-31 Zuvachem, Inc. High efficiency isoprene synthases produced by protein engineering
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CN105473723A (en) * 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof

Also Published As

Publication number Publication date
BR112020007698A2 (en) 2020-10-06
JP2021500911A (en) 2021-01-14
KR20200083510A (en) 2020-07-08
JP7438943B2 (en) 2024-02-27
EP3703722A1 (en) 2020-09-09
AU2018359492A1 (en) 2020-04-16
US20200323977A1 (en) 2020-10-15
MX2020004492A (en) 2020-11-24
IL274220A (en) 2020-06-30
US11872281B2 (en) 2024-01-16
AU2018359492B2 (en) 2023-12-14
CN111356466A (en) 2020-06-30
CA3079210A1 (en) 2019-05-09
EA202091104A1 (en) 2020-08-12
WO2019086450A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
ZA202002184B (en) Adenovirus and uses thereof
ZA202002191B (en) Adenovirus and uses thereof
IL274218A (en) Adenovirus vectors and uses thereof
ZA201908301B (en) Biomarkers and uses thereof
IL273236A (en) Pyrazolopyrimidinone compounds and uses thereof
IL273510A (en) Combination therapies and uses thereof
IL293377B1 (en) Hsd17b13 variants and uses thereof
GB201713765D0 (en) Modified adenovirus
IL274220A (en) Adenovirus and uses thereof
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL264473A (en) Gpr156 variants and uses thereof
GB2584009B (en) Aminoglycosides and uses thereof
GB202004930D0 (en) Composition and uses thereof
IL275211A (en) Fast and partition-resilient blockchains
IL273671A (en) Cornulin (crnn) variants and uses thereof
IL269836B (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
ZA201905511B (en) Rorgamma modulators and uses thereof
ZA201905513B (en) Rorgamma modulators and uses thereof
IL269843B (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
GB201708741D0 (en) Biomarkers and uses thereof
GB201508028D0 (en) Sandfalls and the like
GB201706219D0 (en) Modified adenovirus
GB201707279D0 (en) Multiearphones and polyearphones
GB201700663D0 (en) Modified adenovirus
GB201716745D0 (en) New formulations and uses thereof